Hepatology · Article 181

Who Should Be Treated for Chronic Hepatitis B in 2026?

Chronic hepatitis B treatment requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Chronic hepatitis B treatment clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Chronic hepatitis B treatment: practical clinical approach

This page focuses on Chronic hepatitis B treatment with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Chronic hepatitis B treatment

Clinical takeaway: For Chronic hepatitis B treatment, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Antiviral therapy is clearly indicated for chronic hepatitis B with cirrhosis and detectable HBV DNA, and for immune-active disease. The 2025 AASLD/IDSA guideline also broadens consideration of treatment in patients previously labeled immune tolerant or indeterminate. HBeAg-positive patients with very high HBV DNA and normal ALT should be considered for treatment when age is 40 years or older or significant inflammation/fibrosis is present. HBeAg-negative indeterminate-phase adults should undergo shared decision-making, with age, sex, fibrosis and platelet count influencing the balance.

Treat cirrhosis aggressively

Patients with cirrhosis should not wait for a major ALT flare before antiviral therapy. Viral suppression reduces decompensation and HCC risk.

Immune-active disease remains a clear indication

For HBeAg-positive patients without cirrhosis, HBV DNA ≥20,000 IU/mL with ALT >2× ULN is a classic treatment pattern. HBeAg-negative immune-active disease generally uses a lower HBV DNA threshold.

The gray zone has changed

The 2025 guideline explicitly moves selected immune-tolerant and indeterminate patients toward treatment rather than passive lifelong observation.

Practical clinical algorithm

1. Determine HBeAg status, HBV DNA and ALT pattern.

2. Stage fibrosis with elastography or another validated method.

3. Treat cirrhosis and immune-active disease.

4. In immune-tolerant HBeAg-positive disease, consider treatment at age ≥40 or with ≥F2 fibrosis/significant inflammation.

5. For HBeAg-negative indeterminate disease, use shared decision-making and reassess at every visit.

6. Use a high-barrier nucleos(t)ide analogue when therapy is chosen.

Common mistakes to avoid

Treating only when ALT is dramatically elevated.
Calling normal ALT proof of harmless disease.
Ignoring fibrosis assessment.
Failing to reconsider treatment as age and fibrosis change.
Using low-barrier antivirals when better options are available.

Trainee takeaway

Modern HBV treatment is risk-based, not ALT-based alone; fibrosis, age and long-term HCC risk now matter more explicitly.

Frequently asked questions

Does every HBsAg-positive patient need therapy?

No. Some inactive patients can be monitored safely.

Does normal ALT exclude progressive HBV?

No.

What drugs are preferred?

Entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide are high-barrier first-line agents.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Practice Review in Hepatopancreaticobiliary Diseases and Nutrition. CAPstone Academic Publishers; 2014.

3. Ghany MG, Pan CQ, Lok AS, et al. AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B. Hepatology. 2026;83:974-997. doi:10.1097/HEP.0000000000001549.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions